Clinical Trial Update: Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Fruquintinib plus FOLFIRI in RAS-mutated metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• Fruquintinib (fruquintinib)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Colorectal Cancer | Phase 2 | Status: UNKNOWN